VIVO - Meridian Bio to acquire urea breath test for H. pylori for $20M

Meridian Bioscience ([[VIVO]]) has signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical for $20M in cash.The transaction is expected to close in Meridian’s fiscal Q4. With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.The acquisition is expected to add more than $20M of annual revenue, strengthening Meridian’s position as a provider of gastrointestinal diagnostic solutions, and is expected to be accretive to earnings and cash immediately.

For further details see:

Meridian Bio to acquire urea breath test for H. pylori for $20M